ACR Convergence 2024

November 14-19, 2024. Washington, DC.

View by Number View by Title View Sessions

Sunday, November 17, 2024

10:30AM-12:30PM: Abstract Number: 1251

Current Disease Management and Treatment Satisfaction in Axial Spondyloarthritis (axSpA) in Europe: Patient and Rheumatologist Perspectives

Patient Outcomes, Preferences, & Attitudes Poster II

10:30AM-12:30PM: Abstract Number: 1388

CXC Chemokine Ligand 13 and Rheumatoid Factor as Pharmacodynamic Biomarkers for Abatacept Treatment in Patients with Rheumatoid Arthritis

RA – Treatment Poster II

10:30AM-12:30PM: Abstract Number: 0881

Cytokine Profile of Newly Diagnosed Patients with Isolated Polymyalgia Rheumatica

Cytokines & Cell Trafficking Poster

10:30AM-12:30PM: Abstract Number: 0943

Cytosporone B, a Selective Agonist of Nr4a1, Inhibits Th17 Differentiation and Alleviates Experimental Arthritis in SKG Mice

Rheumatoid Arthritis – Animal Models Poster

10:30AM-12:30PM: Abstract Number: 1073

Dashboard Utilization and Order Menu Revision Improve HLA-B*5801 Testing Prior to Allopurinol Initiation in High-Risk Patients in a Veteran-based Primary Care Setting

Measures & Measurement of Healthcare Quality Poster

10:30AM-12:30PM: Abstract Number: 0941

DC-9476, a Novel Selective BRD4(BD2) Inhibitor, Improves Arthritis Scores in Preclinical Models of Rheumatoid Arthritis by Regulating Key Inflammatory Pathways

Rheumatoid Arthritis – Animal Models Poster

10:30AM-12:30PM: Abstract Number: 1333

Deciphering Variation in Real-World Early RA Outcomes: A Longitudinal Analysis of the Canadian Early Arthritis Cohort (CATCH) Study

RA – Diagnosis, Manifestations, & Outcomes Poster II

10:30AM-12:30PM: Abstract Number: 1570

Deconvolution of the Lipidomic Signature of Very Early Diagnosis of Systemic Sclerosis (VEDOSS) and Established Disease: Lipid Biomarker Features That Predict Disease Progression in Skin and Lung

Systemic Sclerosis & Related Disorders – Clinical Poster II

10:30AM-12:30PM: Abstract Number: 0921

Deep Immunologic Profiling of Trisomy 8-associated Autoinflammatory Disease (TRIAD)

Innate Immunity Poster

10:30AM-12:30PM: Abstract Number: 1141

Defining a Novel Type of Myositis: Immune Mediated Megaconial Myopathy (IMMM)

Muscle Biology, Myositis & Myopathies – Basic & Clinical Science Poster II

10:30AM-12:30PM: Abstract Number: 0904

Defining the Function of Disease Variants with CRISPR Editing and Multimodal Single Cell Sequencing

Genetics, Genomics & Proteomics Poster

10:30AM-12:30PM: Abstract Number: 1606

Demographic and Treatment Patterns in Patients with Eosinophilic Granulomatosis with Polyangiitis: A Retrospective Cohort Analysis of US Claims and Clinical Data

Vasculitis – ANCA-Associated Poster II

10:30AM-12:30PM: Abstract Number: 1007

Demographic, Social, and Disease Factors Associated with Interstitial Lung Disease and Disease-Related Death in Dermatomyositis

Epidemiology & Public Health Poster II

10:30AM-12:30PM: Abstract Number: 1002

Depression Screening in Patients with Rheumatologic Diseases in a Large Tertiary Care Center

Epidemiology & Public Health Poster II

10:30AM-12:30PM: Abstract Number: 0970

Deubiquitylase (DUB) BRCC36 Isopeptidase Complex (BRISC) Inhibitors Prevent IFNAR1 Deubiquitination to Restore Natural Type I IFN Response in Autoimmunity

Systemic Sclerosis & Related Disorders – Basic Science Poster I

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].